Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...

The "Cerebral Palsy - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of Cerebral Palsy Clinical ...

ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- ...

Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the first patient has been dosed in its ...

More than one in three adults in the UK suffers from chronic pain — just under 28 million people, according to the National ...

GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed  Additional data evaluating GEO-CM04S1 as ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual results and recent business updates. Business ...

Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for Prader-Willi syndrome (PWS), a rare genetic ...

In recent years, the pharmaceutical industry has undergone a major transformation in research and development approaches, ...

The company presented its results this week at a conference and anticipates that with additional validation early next year, it will be ready to file for regulatory approval.